Clinical trials: COPD
Chronic Obstructive Pulmonary Disease (COPD)
Confirmatory Study of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)
This study was designed to provide pivotal confirmation of efficacy and safety data for 2 doses of indacaterol (150 and 300 µg once daily [od]) in patients with moderate to severe chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT00794157
- Testing
- Indacaterol 150 μg capsules, Indacaterol 300 μg capsules
- Where
- 60 sites in Hong Kong, India and 4 more
- Volunteers
- 347 people
- Sponsor
- Novartis Pharmaceuticals
COPD
Study to Assess the Safety and Efficacy of PT010, PT003, and PT009 in Japanese Subjects With COPD Compared With Symbicort® Turbohaler®
A Randomized, Double-Blind, Parallel Group, 28-Week Chronic Dosing, Multi-Center Long-term Extension Study to Assess the Safety and Efficacy in Japanese Subjects with Moderate to Very Severe Chronic Obstructive Pulmonary Disease…
- Trial name
- NCT03262012
- Testing
- BGF MDI (PT010), GFF MDI (PT003), BFF MDI (PT009)
- Where
- 79 sites in Japan
- Volunteers
- 416 people
- Sponsor
- Pearl Therapeutics, Inc.
COPD, Chronic Obstructive Pulmonary Disease
Trial to Assess the Anti-inflammatory Effects of Roflumilast in Chronic Obstructive Pulmonary Disease
The objective of the Biopsy trial is to investigate the effect of roflumilast 500 µg tablets once daily versus placebo on inflammation parameters in bronchial biopsy tissue specimen and additional in sputum and blood serum.
- Trial name
- NCT01509677
- Testing
- Roflumilast
- Where
- 20 sites in Denmark, Germany and 3 more
- Volunteers
- 158 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease, Pulmonary Fibrosis
Using Health-related Quality of Life (HRQL) in Routine Clinical Care
The objective of this study is to assess the effects of using HRQL measures in the clinical care of pre- and post-lung transplant patients.
- Conditions
- Chronic Obstructive Pulmonary Disease, Pulmonary Fibrosis, Pulmonary Hypertension, Cystic Fibrosis
- Trial name
- NCT00457301
- Testing
- HUI score card
- Where
- Canada
- Volunteers
- 213 people
- Sponsor
- University of Alberta
Pulmonary Disease, Chronic Obstructive
The ENERGITO® 2 Study Compares 2 Inhaled Medicines for Chronic Obstructive Pulmonary Disease (COPD). One Medicine is a Combination of Tiotropium and Olodaterol (Stiolto®) Taken Using the Respimat® Inhaler and the Other Medicine is a Combination of Fluticasone and Salmeterol Taken Using the Diskus
The primary objective of the trial is to show superiority in lung function of once daily (2 inhalations) treatment with orally inhaled tiotropium+olodaterol fixed dose combination to twice daily (one inhalation) treatment with…
- Trial name
- NCT03240575
- Testing
- Tiotropium, Olodaterol, Fluticasone propionate
- Where
- 45 sites in United States
- Volunteers
- 302 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive, Asthma
Efficacy and Safety of 4 Weeks Treatment With Inhaled BI 1744 CL in Patients With COPD.
The primary objective of this study is to determine the optimum dose(s) of BI 1744 CL inhalation solution delivered by the Respimat® inhaler for four weeks in patients with chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT00452400
- Testing
- BI 1744CL
- Where
- 42 sites in United States, Canada and 2 more
- Volunteers
- 409 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate (FF) /GW642444 (Vilanterol) (VI) Inhalation Powder 100/25mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease
The purpose of this study is to evaluate the 24-hour spirometry effect (FEV1) of FF/VI 100/25mcg once daily compared with Fluticasone Propionate/Salmeterol 250/50mcg twice daily over a 12-week treatment period in subjects with…
- Trial name
- NCT01323634
- Testing
- Fluticasone Furoate 100mcg / GW642444 (vilanterol) 25mcg, Fluticasone Propionate 250mcg/ salmeterol 50mcg
- Where
- 50 sites in United States, Czechia and 4 more
- Volunteers
- 519 people
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
A Study to Evaluate the Safety, Efficacy and Changes in Induced Sputum and Blood Biomarkers Following Daily Repeat Doses of Inhaled GSK2269557 in Chronic Obstructive Pulmonary Disease (COPD) Subjects With Acute Exacerbation
The purpose of this study is to evaluate specific alterations in immune cell mechanisms related to neutrophil function as detected by PI3Kdelta-dependent changes in messenger ribonucleic acid (mRNA) extracted from induced sputum…
- Trial name
- NCT02522299
- Testing
- GSK2269557, DISKUS, ELLIPTA
- Where
- 6 sites in Canada, Denmark
- Volunteers
- 44 people
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease
A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
Phase II, randomized, double-blind, placebo-controlled, parallel-group clinical trial of lebrikizumab in participants with COPD and a history of exacerbations who are treated with inhaled corticosteroid (ICS) and at least one…
- Trial name
- NCT02546700
- Testing
- Lebrikizumab
- Where
- 63 sites in United States, Argentina and 7 more
- Volunteers
- 309 people
- Sponsor
- Hoffmann-La Roche
Asthma, Chronic Obstructive Pulmonary Disease (COPD)
Comparative Effectiveness of Telemedicine in Primary Care
Leveraging a natural experiment approach, the investigators will examine rapidly changing telemedicine and in-person models of care during and after the COVID-19 crisis to determine whether certain patients could safely choose to…
- Conditions
- Asthma, Chronic Obstructive Pulmonary Disease (COPD), Congestive Heart Failure, Diabetes
- Trial name
- NCT04684836
- Testing
- Exposure to telemedicine, after the onset of the pandemic
- Where
- 4 sites in United States
- Volunteers
- 33,100 people
- Sponsor
- Weill Medical College of Cornell University
Chronic Obstructive Pulmonary Disease (COPD)
A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary Disease
This study will evaluate the efficacy and safety of astegolimab compared with placebo in participants with chronic obstructive pulmonary disease (COPD) who are former or current smokers and have a history of frequent…
- Trial name
- ARNASA (NCT05595642)
- Testing
- Astegolimab
- Where
- 348 sites in United States, Argentina and 34 more
- Volunteers
- 1,380 people
- Sponsor
- Hoffmann-La Roche
COPD Exacerbation Acute
Treatment of Pneumocystis in COPD (the TOPIC Study)
Chronic obstructive pulmonary disease (COPD) is a progressive lung disease associated with chronic inflammation in the airways and lung, resulting in significant morbidity and mortality worldwide.
- Trial name
- NCT05418777
- Testing
- Trimethoprim Sulfamethoxazole
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Corewell Health East
Pulmonary Disease, Chronic Obstructive
Dose-Finding Study of Batefenterol (GSK961081) Via Dry Powder Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Batefenterol is a novel bifunctional molecule that combines muscarinic antagonism and beta2-agonism in a single molecule. This is a multicenter, randomized, placebo-controlled, double-blind, parallel group study primarily…
- Trial name
- NCT02570165
- Testing
- Batefenterol, Umeclidinium/ Vilanterol
- Where
- 25 sites in United States, Germany and 1 more
- Volunteers
- 325 people
- Sponsor
- GlaxoSmithKline
Anxiety
Anxiety Self-Management for ICU Patients Receiving Mechanical Ventilation
The purpose of this study is to test whether patients who are receiving mechanical ventilation in the ICU who listened to preferred, relaxing music whenever they desire for as long as they desire will have less anxiety, receive…
- Trial name
- NCT00440700
- Testing
- Anxiety Self-Management, Patient preferred relaxing music, Control 1: Noise-cancelling headphones, Control 2: Standard of Care
- Where
- United States
- Volunteers
- 364 people
- Sponsor
- University of Minnesota
Chronic Obstructive Pulmonary Disease
Vibratory PEP Device and Hospital Length of Stay for Acute Exacerbation of COPD
This study is evaluating the use of a respiratory device, the Acapella Vibratory Positive Expiratory Pressure (PEP) Therapy device, in patients admitted to the hospital with a chronic obstructive pulmonary disease (COPD)…
- Trial name
- NCT03094806
- Testing
- Acapella Vibratory PEP Therapy Device plus usual care
- Where
- United States
- Volunteers
- 91 people
- Sponsor
- New York Presbyterian Brooklyn Methodist Hospital
Chronic Obstructive Pulmonary Disease (COPD)
Targeted Retreatment of COPD Exacerbations
This study investigates the effects of targeted re-treatment of patients who do not recover from an exacerbation of COPD. Half of the patients will receive ciprofloxacin while the other half will receive a placebo.
- Trial name
- NCT02300220
- Testing
- Ciprofloxacin
- Where
- 4 sites in United Kingdom
- Volunteers
- 144 people
- Sponsor
- Imperial College London